| Identification | Back Directory | [Name]
Disodium (7R)-7-[[4-(carbamoyl-carboxylato-methylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | [CAS]
74356-00-6 | [Synonyms]
Cefotetan disodi
CEFOTETAN DISODIUM
Cefotetan DisodiuM Sterile
Cefotan in plastic container
Cefotetan and dextrose in duplex container
Disodium (7R)-7-[[4-(carbamoyl-carboxylato-methylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[[4-(2-aMino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl]aMino]-7-Methoxy-3-[[(1-Methyl-1H-tetrazol-5-yl)thio]Methyl]-8-oxo-,sodiuM salt (1:2), (6R,7S)-
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl)carbonyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, disodium salt, (6R-(6alpha,7alpha))- | [EINECS(EC#)]
277-834-9 | [Molecular Formula]
C17H15N7Na2O8S4 | [MDL Number]
MFCD00941449 | [MOL File]
74356-00-6.mol | [Molecular Weight]
619.583 |
| Hazard Information | Back Directory | [Definition]
ChEBI: The disodium salt of cefotetan. | [Description]
Cefotetan disodium is a β-lactamase resistant, second generation cephalosporin
with a serum half-life of about three hours, permitting twice-daily dosing. | [Originator]
Yamanouchi (Japan) | [Uses]
Antibacterial. | [Uses]
Cefotetan Disodium is a related compound of Cefotetan (C242970), an antibiotic related to Cephalosporin that is used to treat bacterial infections. | [Brand name]
Cefotan (AstraZeneca);YAMATETAN. | [Clinical Use]
Cefotetan (Cefotan) is a third-generation cephalosporin thatis structurally similar to cefoxitin. Like cefoxitin, cefotetanis resistant to destruction by β-lactamases. It is also a competitiveinhibitor of many β-lactamases and causes transient inactivation of some of these enzymes. Cefotetan is reportedto synergize with β-lactamase–sensitive β-lactams but, unlikecefoxitin, does not appear to cause antagonism.
The antibacterial spectrum of cefotetan closely resemblesthat of cefoxitin. It is, however, generally more activeagainst S. aureus, and members of the Enterobacteriaceaefamily sensitive to both agents. It also exhibits excellentpotency against H. influenzae and N. gonorrhoeae, includingβ-lactamase–producing strains. Cefotetan is slightly lessactive than cefoxitin against B. fragilis and other anaerobes.Enterobacter spp. are generally resistant to cefotetan, andthe drug is without effect against Pseudomonas spp.Cefotetan has a relatively long half-life of about 3.5hours. It is administered on a twice-daily dosing schedule. Itis excreted largely unchanged in the urine. Aqueoussolutions for parenteral administration maintain potency for24 hours at 25°C. Refrigerated solutions are stable for 4 days.
Cefotetan contains the MTT group that has been associatedwith hypoprothrombinemia and alcohol intolerance.Another cephalosporin that lacks these properties should beselected for patients at risk for severe bleeding or alcoholism. | [Veterinary Drugs and Treatments]
Cefotetan may be a reasonable choice for treating serious infections
caused by susceptible bacteria, including E. coli or anaerobes.
It appears to be well tolerated in small animals and may be given
less frequently than cefoxitin. |
|
|